Plain-English translation of NCT07484204 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called AX251, which is given as a long-acting injection (a single shot that releases medicine slowly over time). The study wants to understand how your body processes this medication, whether it's safe, and how well you tolerate it. Researchers will give different doses to different groups of people to find the right amount.
Currently, people with schizophrenia often have to take daily pills, which can be hard to remember and do consistently. This medication is designed as a long-acting injection so you would need fewer doses, making treatment simpler and helping people stay stable on their medicine.
You likely qualify if…
You likely don't qualify if…
You would come to the study site and receive a single injection of the medication. You would need to stay at the site for 7 days after the injection so researchers can carefully monitor how your body responds, take blood samples, and check your vital signs and symptoms. Throughout the study, doctors will assess your safety and how well you tolerate the medication at different dose levels.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
India